Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mercaptopurine for Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)
NCT07716735Phase 1Not yet recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2026
- Primary completion
- Dec 2034
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mercaptopurine in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), renal cell carcinoma (RCC), uterine leiomyoma and 1 more, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Maximum tolerated dose at 8 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
mercaptopurine
03
Conditions
Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)renal cell carcinoma (RCC)uterine leiomyomaCutaneous Leiomyoma (CLM)
Beyond the preview
Go deeper on NCT07716735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07716735.